Faes Farma
FAE.MCPhase 3Faes Farma is a leading, publicly traded Spanish pharmaceutical group with a holistic approach to health, encompassing human pharmaceuticals, consumer healthcare, and animal nutrition. With a foundation built on over 90 years of innovation, the company has developed key proprietary drugs like Bilastine and Calcifediol, and maintains a strong global footprint with direct operations in Iberia, Latin America, and Africa-Middle East. The company is strategically focused on R&D, sustainability, and expanding its portfolio in therapeutic areas such as allergy, gastroenterology, immunology, and pain management, while also growing its animal nutrition business to support sustainable food production.
FAE.MC · Stock Price
Historical price data
AI Company Overview
Faes Farma is a leading, publicly traded Spanish pharmaceutical group with a holistic approach to health, encompassing human pharmaceuticals, consumer healthcare, and animal nutrition. With a foundation built on over 90 years of innovation, the company has developed key proprietary drugs like Bilastine and Calcifediol, and maintains a strong global footprint with direct operations in Iberia, Latin America, and Africa-Middle East. The company is strategically focused on R&D, sustainability, and expanding its portfolio in therapeutic areas such as allergy, gastroenterology, immunology, and pain management, while also growing its animal nutrition business to support sustainable food production.
Technology Platform
Integrated pharmaceutical development and manufacturing platform specializing in chemical synthesis, formulation science, and microencapsulation technology for drug delivery and animal nutrition products.
Pipeline
17| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Bilastine + Desloratadine + Placebo | Seasonal Allergic Rhinitis | Phase 3 | |
| Hemorrane plus + Hemorrane + Placebo | Haemorrhoids Without Complication | Phase 3 | |
| Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic So... | Allergic Conjunctivitis | Phase 3 | |
| Mesalazine | Colitis, Ulcerative | Phase 3 | |
| Bilastine + Placebo | Allergic Conjunctivitis | Phase 3 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Faes Farma competes in the human pharma sector against large multinationals (e.g., J&J, Sanofi) and generics makers, differentiating through its proprietary Bilastine. In animal nutrition, it competes with global agribusiness giants (e.g., Cargill, ADM) by specializing in technologically advanced piglet nutrition solutions.